Market Overview

New Lawsuit Alleges Celgene Schemed Charities 'To Gain Billions' Of Dollars

New Lawsuit Alleges Celgene Schemed Charities 'To Gain Billions' Of Dollars
Related CELG
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Market In 5 Minutes: GE, Tariffs, Summit, Jobless Claims And More
Mining ASCO 2018's Gold, Part 4: Radiation Glows In Breast And Brain (Seeking Alpha)

Celgene Corporation (NASDAQ: CELG) is the target of a lawsuit, according to a report by Bloomberg, in which the company is alleged to have donated hundreds of millions of dollars to various charities, as "part of a core business scheme to gain billions" of dollars from taxpayers.

The allegations come from a former Celgene sales representative, Beverly Brown. She claims Celgene would coordinate with the charities in question to ensure that its medicines were covered. By doing so, the company may have violated federal law, as it would collect billions of dollars from Medicare and other health plans.

A Celgene spokesman, Brian Gill, told Bloomberg in an e-mail the allegations are both "wrong" and "baseless." He added that the company followed all necessary federal rules and regulations in its charitable donations.

Bloomberg also cited Celgene's legal filings, which state the company is active in charities, because a core value it shares is to "ensure that cancer patients have access to medicines they need.

Related Link: Short Sellers Shy Away From These 2 Biotechs This Settlement Period

Celgene's lawyers also stated that criticism directed toward the company is merely a "classic example of no good deed shall go unpunished."

Shares of Celgene were trading lower by nearly 1 percent at $111.28 ahead of Monday's stock market open, but within the first hour of regular trading, shares were up 2.01 percent at $114.44.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Posted-In: Bloomberg Brian GillBiotech News Health Care Legal Media General Best of Benzinga


Related Articles (CELG)

View Comments and Join the Discussion!